Unicycive Therapeutics Announced It Has Entered Into A Securities Purchase Agreement With Certain Healthcare-focused Institutional Investors For The Sale Of 50,000 Shares Of Its Series B Convertible Preferred Stock At An Offering Price Of $1,000 Per Share
Unicycive Therapeutics宣布已与某些以医疗保健为重点的机构投资者签订证券购买协议，以每股1,000美元的发行价出售其B系列可转换优先股的50,000股股票